The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer is offering a new rapid mutation test for somatic IDH1 mutations in patients with newly diagnosed Acute Myeloid Leukemia (AML), facilitating the on-label use of ivosidenib (Tibsovo®).
IDH1 will now be included with the FLT3 ITD/ TKD and NPM1 rapid mutation test for newly diagnosed patients with AML. This testing will automatically be performed for all patients undergoing FLT3 and NPM1 testing. Note: Patients with relapsed or refractory AML are not eligible for testing however, FLT3-ITD and FLT3-TKD testing remains available for Relapsed/ Treatment Refractory AML.
This test will detect the 5 most common mutations in IDH1 at codon 132 (R132C/H/G/L/S). Other mutations in IDH1 that are not targeted by this assay can be detected by the more comprehensive myeloid panel. Additional information on this testing can be found in our memo. Further details about this IDH1 Mutation Screen and Rapid Mutation Panel can be found here.
Rapid AML Mutation panel for IDH1 mutations can be ordered using the existing CGL Myeloid Requisition, available on our Requisitions page.